Catalyst Wire Dossier Catalyst Wire Dossier

Emavusertib (CA-4948)

emavusertib
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Emavusertib (CA-4948), covering 2026-04-03 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer [Phase 1]

See pricing